Wilkinson-Berka JL - Search Results

1

Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy.

Deliyanti D, Alrashdi SF, Tan SM, Meyer C, Ward KW, de Haan JB, Wilkinson-Berka JL. Deliyanti D, et al. Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):815-825. doi: 10.1167/iovs.17-22920. Invest Ophthalmol Vis Sci. 2018. PMID: 29411009

2

Four-week inhibition of the renin-angiotensin system in spontaneously hypertensive rats results in persistently lower blood pressure with reduced kidney renin and changes in expression of relevant gene networks.

Byars SG, Prestes PR, Suphapimol V, Takeuchi F, De Vries N, Maier MC, Melo M, Balding D, Samani N, Allen AM, Kato N, Wilkinson-Berka JL, Charchar F, Harrap SB. Byars SG, et al. Among authors: wilkinson berka jl. Cardiovasc Res. 2024 May 29;120(7):769-781. doi: 10.1093/cvr/cvae053. Cardiovasc Res. 2024. PMID: 38501595 Free PMC article.

3

COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity.

Wilkinson-Berka JL, Alousis NS, Kelly DJ, Gilbert RE. Wilkinson-Berka JL, et al. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):974-9. doi: 10.1167/iovs.02-0392. Invest Ophthalmol Vis Sci. 2003. PMID: 12601017

4

The renin-angiotensin system and the developing retinal vasculature.

Sarlos S, Wilkinson-Berka JL. Sarlos S, et al. Invest Ophthalmol Vis Sci. 2005 Mar;46(3):1069-77. doi: 10.1167/iovs.04-0885. Invest Ophthalmol Vis Sci. 2005. PMID: 15728567

5

SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.

Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, Ludbrook SB, Willette RN, Kumar S, Gilbert RE. Wilkinson-Berka JL, et al. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5. doi: 10.1167/iovs.05-1314. Invest Ophthalmol Vis Sci. 2006. PMID: 16565398

6

Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.

Phipps JA, Wilkinson-Berka JL, Fletcher EL. Phipps JA, et al. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):927-34. doi: 10.1167/iovs.06-0892. Invest Ophthalmol Vis Sci. 2007. PMID: 17251496

7

Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function.

Miller AG, Tan G, Binger KJ, Pickering RJ, Thomas MC, Nagaraj RH, Cooper ME, Wilkinson-Berka JL. Miller AG, et al. Diabetes. 2010 Dec;59(12):3208-15. doi: 10.2337/db10-0552. Epub 2010 Sep 17. Diabetes. 2010. PMID: 20852029 Free PMC article.

8

Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat.

Wilkinson-Berka JL, Tan G, Binger KJ, Sutton L, McMaster K, Deliyanti D, Perera G, Campbell DJ, Miller AG. Wilkinson-Berka JL, et al. Diabetologia. 2011 Oct;54(10):2724-35. doi: 10.1007/s00125-011-2239-9. Epub 2011 Jul 14. Diabetologia. 2011. PMID: 21755314

9

Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy.

Deliyanti D, Miller AG, Tan G, Binger KJ, Samson AL, Wilkinson-Berka JL. Deliyanti D, et al. Hypertension. 2012 Mar;59(3):607-13. doi: 10.1161/HYPERTENSIONAHA.111.188136. Epub 2012 Jan 23. Hypertension. 2012. PMID: 22275532

10

The retinal renin-angiotensin system: roles of angiotensin II and aldosterone.

Wilkinson-Berka JL, Agrotis A, Deliyanti D. Wilkinson-Berka JL, et al. Peptides. 2012 Jul;36(1):142-50. doi: 10.1016/j.peptides.2012.04.008. Epub 2012 Apr 17. Peptides. 2012. PMID: 22537944 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

107 results

Search Page

Filters